Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.36 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.36 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7215103 | 0.86 | L3MBTL1 (0.68) | L3MBTL1NPC1LMNAALDH1A1HPGD | |
| SCHEMBL5664989 | 0.84 | L3MBTL1 (0.50) | L3MBTL1NPC1LMNAALDH1A1HPGD | |
| SCHEMBL6166493 | 0.78 | LMNA (0.45) | L3MBTL1NPC1LMNAALDH1A1HPGD | |
| SCHEMBL5664796 | 0.78 | TUBB4A (0.39) | L3MBTL1NPC1ALDH1A1HPGDTRPM8 | |
| SCHEMBL4984172 | 0.77 | TP53 (0.42) | L3MBTL1NPC1LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL4986792 | 0.77 | NPC1 (0.47) | L3MBTL1NPC1LMNAALDH1A1HPGD | |
| SCHEMBL3856122 | 0.76 | TP53 (0.52) | L3MBTL1NPC1LMNAALDH1A1HPGD | |
| SCHEMBL4986055 | 0.74 | NPC1 (0.51) | L3MBTL1NPC1LMNAALDH1A1HPGD | |
| SCHEMBL5010041 | 0.72 | NPC1 (0.43) | L3MBTL1NPC1LMNAALDH1A1HPGD | |
| SCHEMBL5664145 | 0.71 | LTA4H (0.40) | L3MBTL1NPC1ALDH1A1LTB4RLTB4R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040132745-A1 | Microsomal triglyceride transfer protein inhibitor | PFIZER INC | 2004-07-08 | — | — | US | claimed |
| US-20020132806-A1 | 7-[(4'-trifluoromethyl-biphenyl-2-carbonyl)amino]-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein B | RUGGERI ROGER (US) | 2002-09-19 | — | — | US | claimed |
| US-6369075-B1 | 7[4′-trifluoromethyl-biphenyl-2-carbonyl)amino]-quinoline-3-carboxylic acid amides, and method of inhibiting the secretion of apolipoprotein B | PFIZER, INC. | 2002-04-09 | — | — | US | claimed |
| EP-1099701-A1 | 7-[(4'-Trifluoromethyl-biphenyl-2-carbonyl)amino]-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein B | Pfizer Products Inc. (US) | 2001-05-16 | — | — | EP | claimed |
| US-7468378-B2 | Substituted quinoline compounds | PFIZER INC. (US) | 2008-12-23 | — | — | US | disclosed |
| US-7393958-B2 | Triamide-substituted heterobicyclic compounds | PFIZER, INC. (US) | 2008-07-01 | — | — | US | disclosed |
| US-7368573-B2 | Triamide-substituted heterobicyclic compounds | PFIZER INC. (US) | 2008-05-06 | — | — | US | disclosed |
| US-20070093525-A1 | Triamide-substituted heterobicyclic compounds | PFIZER INC | 2007-04-26 | — | — | US | disclosed |
| EP-1716137-A1 | SUBSTITUTED QUINOLINE COMPOUNDS | Pfizer Products Incorporated (US) | 2006-11-02 | — | — | EP | disclosed |
| US-20060223851-A1 | TRIAMIDE-SUBSTITUTED HETEROBICYCLIC COMPOUNDS | BERTINATO PETER | 2006-10-05 | — | — | US | disclosed |
| US-20050234099-A1 | Substituted quinoline compounds | PFIZER INC | 2005-10-20 | — | — | US | disclosed |
| EP-1578725-A1 | MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN INHIBITORS | Pfizer Products Inc. (US) | 2005-09-28 | — | — | EP | disclosed |
| WO-2005080373-A1 | SUBSTITUTED QUINOLINE COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2005-09-01 | — | — | WO | disclosed |
| WO-2004056777-A1 | MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN INHIBITORS | PFIZER PRODUCTS INC. (US) | 2004-07-08 | — | — | WO | disclosed |
| US-20040132745-A1 | Microsomal triglyceride transfer protein inhibitor | PFIZER INC | 2004-07-08 | — | — | US | disclosed |
| US-6713489-B2 | TREATMENT OF ATHEROSCLEROSIS, OBESITY, DIABETES, HYPERLIPIDEMIA, HYPERLIPOPROTEINEMIA, HYPERCHOLESTEROLEMIA, HYPERTRIGLYCERIDEMIA, HYPOALPHALIPOPROTEINEMIA, PANCREATITIS, MYOCARDIAL INFARCTION, STROKE, RESTENOSIS, OR SYNDROME X | PFIZER INC | 2004-03-30 | — | — | US | disclosed |
| US-20020132806-A1 | 7-[(4'-trifluoromethyl-biphenyl-2-carbonyl)amino]-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein B | RUGGERI ROGER (US) | 2002-09-19 | — | — | US | disclosed |
| US-6369075-B1 | 7[4′-trifluoromethyl-biphenyl-2-carbonyl)amino]-quinoline-3-carboxylic acid amides, and method of inhibiting the secretion of apolipoprotein B | PFIZER, INC. | 2002-04-09 | — | — | US | disclosed |
| EP-1099701-A1 | 7-[(4'-Trifluoromethyl-biphenyl-2-carbonyl)amino]-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein B | Pfizer Products Inc. (US) | 2001-05-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132745-A1 | Microsomal triglyceride transfer protein inhibitor | MTTP, CETP, APOB | L3MBTL1 3319/4885NPC1 27/4885LMNA 2237/4885 |
| US-20020132806-A1 | 7-[(4'-trifluoromethyl-biphenyl-2-carbonyl)amino]-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein B | APOB, CETP, PNLIP | L3MBTL1 2698/4885NPC1 70/4885LMNA 2331/4885 |
| US-20050234099-A1 | Substituted quinoline compounds | APOB, APOL1, MTPN | L3MBTL1 1827/4885NPC1 32/4885LMNA 800/4885 |
| US-20060223851-A1 | TRIAMIDE-SUBSTITUTED HETEROBICYCLIC COMPOUNDS | APOB, MTPN, CTRB1 | L3MBTL1 1120/4885NPC1 32/4885LMNA 857/4885 |
| US-20070093525-A1 | Triamide-substituted heterobicyclic compounds | APOB, MTPN, CTRB1 | L3MBTL1 1120/4885NPC1 32/4885LMNA 857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.